Travere Therapeutics (NASDAQ:TVTX – Get Free Report) is expected to be announcing its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect the company to post earnings of ($0.0984) per share and revenue of $195.29 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, November 2, 2026 at 4:30 PM ET.
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.03. The business had revenue of $169.58 million for the quarter, compared to the consensus estimate of $157.27 million. Travere Therapeutics had a negative return on equity of 55.15% and a negative net margin of 7.35%. The company’s revenue was up 48.2% compared to the same quarter last year. During the same period last year, the business posted $0.13 EPS. On average, analysts expect Travere Therapeutics to post ($0.92) EPS for the current fiscal year and $2.49 EPS for the next fiscal year.
Travere Therapeutics Stock Down 0.4%
Travere Therapeutics stock opened at $50.39 on Friday. Travere Therapeutics has a 12 month low of $22.59 and a 12 month high of $68.73. The stock has a fifty day simple moving average of $59.06 and a two-hundred day simple moving average of $46.46. The company has a current ratio of 4.05, a quick ratio of 3.99 and a debt-to-equity ratio of 24.58. The firm has a market cap of $4.75 billion, a price-to-earnings ratio of -109.54 and a beta of 1.13.
Insider Buying and Selling at Travere Therapeutics
In other news, EVP Peter Heerma sold 8,282 shares of the firm’s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $65.07, for a total value of $538,909.74. Following the transaction, the executive vice president directly owned 117,066 shares in the company, valued at $7,617,484.62. This trade represents a 6.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jula Inrig sold 44,674 shares of Travere Therapeutics stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $62.34, for a total value of $2,784,977.16. Following the completion of the sale, the executive vice president directly owned 100,491 shares of the company’s stock, valued at $6,264,608.94. The trade was a 30.77% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 1,294,029 shares of company stock worth $79,454,261. 4.44% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on the company. Piper Sandler reaffirmed an “overweight” rating on shares of Travere Therapeutics in a research report on Monday, August 17th. Zacks Research lowered Travere Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 20th. TD Cowen boosted their target price on Travere Therapeutics from $60.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Canaccord Genuity Group upped their target price on shares of Travere Therapeutics from $62.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Wedbush reaffirmed an “outperform” rating and set a $76.00 price target on shares of Travere Therapeutics in a report on Tuesday, September 22nd. Ten equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $69.50.
View Our Latest Analysis on Travere Therapeutics
About Travere Therapeutics
Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with an emphasis on serious kidney conditions. The company’s work centers on addressing diseases with limited treatment options and improving outcomes for patients with progressive renal disorders.
Travere’s lead commercial product is FILSPARI (sparsentan), an oral treatment for adults with primary immunoglobulin A nephropathy (IgA nephropathy) who are at risk of disease progression.
Read More
- Five stocks we like better than Travere Therapeutics
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
